New antibody takes aim at Hard-to-Treat blood cancers

NCT ID NCT02530034

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live and whether their cancer stays away.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hu8F4 (a monoclonal antibody)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced blood cancers that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial with only 72 participants, so it is primarily testing safety and dosing. It may not show strong anti-cancer effects, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm myelodysplastic syndrome myelodysplastic syndrome with excess blasts-1 myelodysplastic syndrome with excess blasts-2 myelofibrosis primary myelofibrosis therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM HIGH RISK MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1 MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-2 MYELOFIBROSIS RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA SECONDARY ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Locations

Augusta University

Augusta, Georgia, 30912, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States
Montefiore Medical Center, Albert Einstein College of Medicine

The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.